http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003166515-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-645 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-64 |
| filingDate | 2003-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08ca2dff8975841a629cefd185a7298a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6ae224073fa9ba2acc22ba3a80c75b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69c0d8326ed787cf47a2563c5f74f0dc |
| publicationDate | 2003-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003166515-A1 |
| titleOfInvention | Cyclosporins for the treatment of immune disorders |
| abstract | The present invention relates to methods of treating or preventing an inflammatory or immune disorder in a subject while eliminating or reducing the toxicity associated with the administration of cyclosporin A, comprising systemically administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof, in combination with a pharmaceutically-acceptable carrier or excipient: n n n in Formula I, the Formula for residue A is: n n n where X is absent, —C 1 -C 6 alkyl-, or —C 3 -C 6 cycloalkyl-; Y is selected from the groups: —C(O)—O—R 1 where R 1 is hydrogen, C 1 -C 6 alkyl optionally substituted with halogen, heterocyclics, aryl, C 1 -C 6 alkoxy or C 1 -C 6 alkylthio, halogen substituted C 1 -C 6 alkoxy or halogen substituted C 1 -C 6 alkylthio; —C(O)—S—R 1 where R 1 is hydrogen, C 1 -C 6 alkyl optionally substituted with halogen, heterocyclics, aryl, C 1 -C 6 alkoxy or C 1 -C 6 alkylthio, halogen substituted C 1 -C 6 alkoxy or halogen substituted C 1 -C 6 alkylthio; —C(O)—OCH 2 —OC(O)R 2 where R 2 is C 1 -C 6 alkyl optionally substituted with halogen, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, heterocyclics, or aryl; —C(S)—O—R 1 where R 1 is hydrogen, C 1 -C 6 alkyl optionally substituted with halogen, heterocyclics, aryl, C 1 -C 6 alkoxy or C 1 -C 6 alkylthio, halogen substituted C 1 -C 6 alkoxy or halogen substituted C 1 -C 6 alkylthio; and —C(S)—S—R 1 where R 1 is hydrogen, C 1 -C 6 alkyl optionally substituted with halogen, heterocyclics, aryl, C 1 -C 6 alkoxy or C 1 -C 6 alkylthio, halogen substituted C 1 -C 6 alkoxy, halogen substituted C 1 -C 6 alkylthio; B is -αAbu-, -Val-, -Thr- or -Nva-; and U is -(D)Ala-, -(D)Ser- or —[O-(2-hydroxyethyl)(D)Ser]-, or —[O-acyl(D)Ser]- or —[O-(2-acyloxyethyl)(D)Ser]-. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7511013-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006035821-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7538084-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006069015-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006069016-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006074015-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7696166-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7696165-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007232531-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007232530-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7361636-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006035822-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7378391-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7226906-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004235716-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008153744-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7632807-B2 |
| priorityDate | 2001-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 304.